What Researchers Did
This review summarized current understandings of hyperbaric oxygen therapy (HBOT) in liver diseases and hepatic regeneration.
What They Found
Most studies reviewed positively evaluated hyperbaric oxygen therapy (HBOT) as a potential treatment for various liver conditions, including liver transplantation, acute liver injury, nonalcoholic steatohepatitis, fibrosis, and cancer, particularly for hepatic artery thrombosis. This benefit is mainly attributed to HBOT's anti-oxidation and anti-inflammation properties, though some controversies exist due to potential hyperbaric oxygen toxicity.
What This Means for Canadian Patients
Canadian patients with liver diseases might potentially benefit from hyperbaric oxygen therapy (HBOT) as an adjuvant treatment in the future. However, more research is needed to establish its safety and efficacy in clinical settings before widespread adoption.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The review acknowledges existing controversies regarding hyperbaric oxygen toxicity and highlights the need for future clinical trials to fully understand HBOT's mechanisms and clinical utility.